- Home
- CDE vs LNTH Comparison
CDE vs LNTH Comparison
Compare CDE & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDE
- LNTH
- Stock Information
- Founded
- CDE 1928
- LNTH 1956
- Country
- CDE United States
- LNTH United States
- Employees
- CDE N/A
- LNTH N/A
- Industry
- CDE Precious Metals
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CDE Basic Materials
- LNTH Health Care
- Exchange
- CDE Nasdaq
- LNTH Nasdaq
- Market Cap
- CDE 5.7B
- LNTH 5.7B
- IPO Year
- CDE N/A
- LNTH 2015
- Fundamental
- Price
- CDE $8.96
- LNTH $71.93
- Analyst Decision
- CDE Strong Buy
- LNTH Strong Buy
- Analyst Count
- CDE 4
- LNTH 5
- Target Price
- CDE $8.94
- LNTH $131.20
- AVG Volume (30 Days)
- CDE 9.7M
- LNTH 1.1M
- Earning Date
- CDE 08-06-2025
- LNTH 08-06-2025
- Dividend Yield
- CDE N/A
- LNTH N/A
- EPS Growth
- CDE N/A
- LNTH N/A
- EPS
- CDE 0.28
- LNTH 3.53
- Revenue
- CDE $1,201,008,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- CDE $70.68
- LNTH $4.57
- Revenue Next Year
- CDE $3.78
- LNTH $9.41
- P/E Ratio
- CDE $32.55
- LNTH $20.46
- Revenue Growth
- CDE 41.80
- LNTH 12.53
- 52 Week Low
- CDE $4.57
- LNTH $69.12
- 52 Week High
- CDE $9.97
- LNTH $118.21
- Technical
- Relative Strength Index (RSI)
- CDE 49.83
- LNTH 38.76
- Support Level
- CDE $8.88
- LNTH $70.40
- Resistance Level
- CDE $9.22
- LNTH $73.52
- Average True Range (ATR)
- CDE 0.35
- LNTH 2.67
- MACD
- CDE -0.06
- LNTH -0.46
- Stochastic Oscillator
- CDE 24.36
- LNTH 19.02
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.